Spectrum Pharmaceuticals, Inc. has filed its twelfth Abbreviated New Drug Application (ANDA), with the US FDA.
Spectrum Pharmaceuticals currently has nine other ANDAs that are under review at the FDA, including an ANDA with Paragraph IV certification for sumatriptan succinate injection, the generic form of GlaxoSmithKline's Imitrex injection, said a company release here.